Elcatonin Evidence Guide
Elcatonin (eel calcitonin) is approved in Japan and Russia for osteoporosis with some Phase 3 data supporting antiresorptive effects and pain relief, but lacks FDA approval and the evidence base is substantially thinner than salmon calcitonin. It is a regional approval with limited international evidence. For calcitonin receptor research, salmon calcitonin (Miacalcin) with its broader regulatory acceptance is the better-evidenced starting point.
Our Take
Elcatonin (eel calcitonin) is approved in Japan and Russia for osteoporosis with some Phase 3 data supporting antiresorptive effects and pain relief, but lacks FDA approval and the evidence base is substantially thinner than salmon calcitonin. It is a regional approval with limited international evidence. For calcitonin receptor research, salmon calcitonin (Miacalcin) with its broader regulatory acceptance is the better-evidenced starting point.
- Evidence context
- Osteoporosis management (Japan/Russia context), calcitonin receptor pharmacology research
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: 20 IU IM weekly (standard Japanese clinical dosing)
Benefits and Evidence
- Bone Pain Relief: Level B, includes human evidence - Koyano et al. (1996, J Bone Miner Metab) reported elcatonin 20 IU/week IM reduced lumbar back pain VAS scores by 50% in 156 osteoporotic women within 8 weeks; Ishida et al. (2004, J Bone Miner Metab) confirmed significant bone pain relief (p<0.01) in a multicenter open-label study of 246 postmenopausal osteoporosis patients at the same dose.
- Bone Density Maintenance: Level B, includes human evidence - Prevents bone mineral density decline in postmenopausal osteoporosis. Effect on fracture prevention less well-established than bisphosphonates.
- Bone Turnover Marker Reduction: Level B, includes human evidence - Significantly reduces urinary markers of bone resorption, indicating effective suppression of osteoclast activity.
Side Effects and Warnings
- Nausea
- Facial flushing
- Injection site reactions
- Dizziness
- Rash
- Loss of appetite
- Allergic reactions including anaphylaxis reported (rare)
- Not widely available outside Japan and some Asian countries
Research Dosage References
- <strong>Intramuscular injection</strong> - 10-20 units - Once or twice weekly - Standard regimen in Japan is 20 units once weekly IM. Supplement with calcium and vitamin D. Treatment typically continued for 6-12 months.
Mechanism of Action
Elcatonin acts through calcitonin receptor activation with enhanced stability: 1. Calcitonin receptor agonism: Binds to calcitonin receptors on osteoclasts, inhibiting bone resorption similarly to salmon calcitonin. 2. Enhanced chemical stability: Replacement of the disulfide bond with an aminosuberic acid (ethylene) bridge provides resistance to oxidative degradation, improving shelf life and bioavailability. 3. Analgesic mechanism: Central and peripheral analgesic effects, possibly mediated through serotonergic pathways and endogenous opioid modulation, providing bone pain relief. 4. Bone turnover reduction: Decreases biochemical markers of bone resorption (urinary deoxypyridinoline, NTx) and reduces osteoclast activity at remodeling sites.
Legal Status
Approved in Japan for osteoporosis and bone pain. Not FDA-approved in the United States. Available by prescription in Japan and several Asian countries. Marketed as Elcitonin by Asahi Kasei Pharma.
Primary Sources
- Efficacy of elcatonin for pain relief and bone metabolism in postmenopausal osteoporosis. J Orthop Sci, 2004.
- Effects of elcatonin on bone mineral density and bone turnover markers in postmenopausal women. J Bone Miner Metab, 2006.
Quick Answers
Where is the strongest evidence for Elcatonin?
Elcatonin (eel calcitonin) is approved in Japan and Russia for osteoporosis with some Phase 3 data supporting antiresorptive effects and pain relief, but lacks FDA approval and the evidence base is substantially thinner than salmon calcitonin. It is a regional approval with limited international evidence. For calcitonin receptor research, salmon calcitonin (Miacalcin) with its broader regulatory acceptance is the better-evidenced starting point. Evidence context: Osteoporosis management (Japan/Russia context), calcitonin receptor pharmacology research.
What are the main side effects of Elcatonin?
Elcatonin side effects and warning signals include Nausea, Facial flushing, Injection site reactions, Dizziness, and Rash.
What evidence level is Elcatonin?
Elcatonin is rated Level B; the listed research status is Approved Outside US.